EXPLANATORY NOTE
On March 23, 2022, pursuant to that certain Agreement and Plan
of Merger by and among the Avista Public Acquisition Corp. II,
Ligand Pharmaceuticals Incorporated, a Delaware corporation
(“Ligand”), OmniAb, Inc., a Delaware corporation and
wholly-owned subsidiary of Ligand (“Legacy OmniAb”), and
Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned
subsidiary of the Registrant (“Merger Sub”), Merger Sub was
merged with and into Legacy OmniAb (the “Merger”) with
Legacy OmniAb surviving the Merger as a wholly-owned subsidiary of
the Registrant. In addition, in connection with the consummation of
the Merger, the Registrant was renamed “OmniAb, Inc.”.
This Registration Statement on Form S-8 (this “Registration
Statement”) registers the offer and sale of (i) 28,409,022
shares of the Registrant’s common stock, par value $0.0001 per
share (“Common Stock”), available for issuance or that may
become available for issuance under the OmniAb, Inc. 2022 Incentive
Award Plan (the “2022 Plan”), including 5,799,496 shares
issuable pursuant to outstanding stock options under the 2022 Plan,
(ii) 4,258,109 shares of Common Stock available for issuance or
that may become available for issuance under the OmniAb, Inc. 2022
Employee Stock Purchase Plan (the “ESPP”), (iii) 5,378,903
shares issuable pursuant to outstanding stock options and 354,337
shares issuable pursuant to outstanding restricted stock units
under the OmniAb, Inc. 2022 Ligand Service Provider Assumed Award
Plan (the “2022 Ligand Assumed Award Plan”), and (iv)
6,922,042 shares issuable pursuant to outstanding stock options and
959,860 shares issuable pursuant to outstanding restricted stock
units under the OmniAb, Inc. 2022 OmniAb Service Provider Assumed
Award Plan (the “2022 OmniAb Assumed Award Plan”, and
together with the 2022 Ligand Assumed Award Plan, the 2022 Plan and
the ESPP, the “Plans”).
PART I
The documents containing the information specified in Items 1 and 2
of this Part I of Form S-8
(plan information and registration information and employee plan
annual information) will be sent or given to employees as specified
by the Securities and Exchange Commission (the “Commission”)
pursuant to Rule 428(b)(1) of the Securities Act. Such documents
are not required to be and are not filed with the Commission either
as part of this Registration Statement or as prospectuses or
prospectus supplements pursuant to Rule 424. These documents and
the documents incorporated by reference in this Registration
Statement pursuant to Item 3 of Part II hereof, taken together,
constitute a prospectus that meets the requirements of
Section 10(a) of the Securities Act. The Company will provide
a written statement to participants advising them of the
availability without charge, upon written or oral request, of the
documents incorporated by reference in Item 3 of Part II hereof and
including the statement in the preceding sentence. The written
statement to all participants will indicate the availability
without charge, upon written or oral request, of other documents
required to be delivered pursuant to Rule 428(b), and will include
the address and telephone number to which the request is to be
directed.
PART II
Item 3. Incorporation of Documents by Reference.
The following documents filed with the Commission are incorporated
as of their respective dates in this Registration Statement by
reference:
|
(a) |
the Registrant’s proxy
statement/prospectus/information statement, dated
September 30, 2022 (the “Prospectus”), filed with the
Commission pursuant to Rule 424(b)(3) promulgated under the
Securities Act in connection with the registration statement on
Form S-4 filed with the
Commission on April 28, 2022, as amended (File No. 333-264525), and all
amendments to such registration statement, which contains the
Registrant’s audited financial statements for the latest fiscal
year for which such statements have been filed;
|
|
(b) |
the Quarterly Reports on Form 10-Q for the quarterly periods ended
March 31, 2022, June 30, 2022, and September 30,
2022, filed with the Commission on
May 20, 2022,
August 12, 2022 and
November 10, 2022, respectively (each, File No. 001-40720);
|